Physician profile
Robert G Hust
NPI 1467451856
$4,915.38
in general payments reported to CMS, 2019-2025
28 companies · $797 in 2025
The $797 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $409 · 2020: $557 · 2021: $1,040 · 2022: $778 · 2023: $458 · 2024: $876 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,085 · Education: $45.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,084.63 |
| Education | $45.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,376.38 | 2021-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Jot Dx |
| Amgen INC. | $512.96 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $450.92 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $356.10 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $295.64 | 2020-2025 | Camzyos, Eliquis |
| Pfizer INC. | $224.42 | 2019-2023 | |
| Esperion Therapeutics, INC. | $202.14 | 2021-2025 | Nexletol |
| Medtronic, INC. | $199.46 | 2024-2025 | Hawkone, Linq II |
| Boston Scientific Corporation | $193.98 | 2020-2021 | |
| Medtronic Vascular, INC. | $168.98 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $150.15 | 2019-2025 | Farxiga, Lokelma |
| Acutus Medical, INC. | $134.64 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.95 | 2021-2025 | Jardiance |
| Novo Nordisk INC | $116.94 | 2024-2025 | Wegovy, Ozempic |
| Tactile Systems Technology INC | $93.36 | 2024-2025 | Flexitouch Plus, Entre Plus, Nimbl |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $53.94 | 2024 | Praluent, Evkeeza |
| Edwards Lifesciences Corporation | $45.00 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $38.27 | 2024 | Arcalyst |
| Altathera Pharmaceuticals LLC | $24.11 | 2022 | |
| Agepha Pharma Fz LLC | $22.69 | 2024 | Lodoco |
| Cvrx, INC. | $18.21 | 2021 | |
| Glaxosmithkline, LLC. | $17.17 | 2025 | Shingrix, Arexvy |
| Irhythm Technologies, INC. | $16.63 | 2024 | Zio Xt Patch |
| Merck Sharp & Dohme LLC | $16.40 | 2022 | |
| Scpharmaceuticals INC. | $15.91 | 2023 | |
| Biosense Webster, INC. | $15.61 | 2023 | Carto 3 |
| Heartflow, INC. | $13.96 | 2020 | |
| Sanofi-Aventis U.S. LLC | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hust listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.